Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 1: 188 - 197

DOI: https://doi.org/10.19852/j.cnki.jtcm.20221013.001

Data Mining

Reveal the mechanisms of prescriptions for liver cancer' treatment based on two illustrious senior TCM physicians

  • Bochuan WANG ,
  • Yong ZHANG ,
  • Qiuyun ZHANG ,
  • Zhiqiang ZHANG ,
  • Changyong LUO ,
  • Zhendong WANG ,
  • Chen BAI ,
  • Yuhan WANG ,
  • Xueyi GE ,
  • Ying QIAN ,
  • He YU ,
  • Xiaohong GU
Expand
  • 1 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 10029, China
    2 Liver Disease Branch, Shandong Hospital of Traditional Chinese Medicine, Jinan 250013, China
    3 School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China
    4 Beijing Tcmages Pharmaceutical Co., Ltd., Beijing 101399, China
    5 Dongfang Hospital Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100078, China
Prof. GU Xiaohong, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 10029, China. guxiaohong1962@163.com. Telephone:+86-18810622544
Prof. YU He, School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 10029, China. yuhe221@126.com;

Received date: 2022-05-05

  Accepted date: 2022-09-21

  Online published: 2023-01-10

Supported by

National Key R&D Program of China Research on Inheritance and Innovation of Experience (Integration of Tao and Shu) of Illustrious Senior Traditional Chinese Medicine Practitioners by adopting Multiple Research Methods(2018YFC1704100);Research on Methodology System and Paradigms for Mining and Inheriting Illustrious Senior Traditional Chinese Medicine Practitioners’ Experience(2018YFC1704101)

Fold

Abstract

OBJECTIVE: To explore the core herbs of two illustrious senior Traditional Chinese Medicine (TCM) Physicians for the treatment of liver cancer, and to further clarify the gene targets and pathway mechanisms of liver cancer that the core prescription (CP) may regulate.
METHODS: We used the patient information of two illustrious senior TCM physicians from the Affiliated Hospital of Shandong University of Traditional Chinese Medicine and the Affiliated Hospital of Capital Medical University as the database. The CP was analyzed using the community network algorithm. The pathway mechanism was analyzed using network pharmacology method. And the prognostic survival genes were identified using Single factor cox regression analysis. Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine (TCMIP), Herb, Online Mendelian Inheritance in Man (OMIM), Genecards, Kyoto Encyclopedia of Genes and Genomes (KEGG), Genomic Data Commons (GDC), The Cancer Genome Atlas (TCGA), Gephi and R were used to mine CP, building a pathway network diagram. All the analyses were visualized.
RESULTS: We found that the CP consistes of Huangqi (Radix Astragali Mongolici), Danshen (Radix Salviae Miltiorrhizae), Shuihonghuazi (Polygoni Orientalis Fructus), Baihuasheshecao (Herba Hedyotdis), Banzhilian (Herba Scutellariae Barbatae), and Ezhu (Rhizoma Curcumae Phaeocaulis), which were attributed to the two physicians respectively. The CP played an anti-cancer role through such pathways as signal transduction, energy metabolism, immune system and other pathways, covering a total of 112 pathways and 176 herb-disease-related genes. Fourteen genes have a significant impact on the prognosis and survival of liver cancer.
CONCLUSION: Based on the liver cancer cases of two illustrious senior TCM physicians, we obtained the CP through data mining. The CP may mainly exert anti-cancer effects by inhibiting inflammatory response, angiogenesis, and enhancing the body's immune response. We screened out 14 genes in the CP that may be related to the prognosis of liver cancer, and these genes may play an important regulatory role in the prognosis of liver cancer.

Key words： liver neoplasms; prognosis; network analysis; bioinformatics analysis; machine learning; medicine, Chinese traditional

Cite this article

Bochuan WANG , Yong ZHANG , Qiuyun ZHANG , Zhiqiang ZHANG , Changyong LUO , Zhendong WANG , Chen BAI , Yuhan WANG , Xueyi GE , Ying QIAN , He YU , Xiaohong GU . Reveal the mechanisms of prescriptions for liver cancer' treatment based on two illustrious senior TCM physicians[J]. Journal of Traditional Chinese Medicine, 2023 , 43(1) : 188 -197 . DOI: 10.19852/j.cnki.jtcm.20221013.001

References

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 2020; 9: 452-63.
3 Liu J, Tang W, Budhu A, et al. A Viral exposure signature defines early onset of hepatocellular carcinoma. Cell 2020; 182: 317-28.
4 Nault JC, Villanueva A. Biomarkers for hepatobiliary cancers. Hepatology 2021; 73: 115-27.
5 Lange N, Dufour JF. Changing epidemiology of hcc: how to screen and identify patients at risk? Dig Dis Sci 2019; 64: 903-9.
6 Reig M, da Fonseca LG, Faivre S. New trials and results in systemic treatment of HCC. J Hepatol 2018; 69: 525-33.
7 Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017; 11: 317-70.
8 Tejeda-Maldonado J, Garcia-Juarez I, Aguirre-Valadez J, et al. Diagnosis and treatment of hepatocellular carcinoma: an update. World J Hepatol 2015; 7: 362-76.
9 Xi SY, Minuk GY. Role of Traditional Chinese Medicine in the management of patients with hepatocellular carcinoma. World J Hepatol 2018; 10: 799-806.
10 Chen X, Wang P, Yang M, et al. Therapeutic effect of Jianpi Liqi Fang combined with transcatheter arterial chemoembolization in patients with hepatocellular carcinoma and spleen deficiency syndrome. J Tradit Chin Med 2021; 41: 157-66.
11 Hu B, Wang SS, Du Q. Traditional Chinese Medicine for prevention and treatment of hepatocarcinoma: from bench to bedside. World J Hepatol 2015; 7: 1209-32.
12 Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 2012; 62: 394-9.
13 Liu X, Li M, Wang X, et al. Effects of adjuvant Traditional Chinese Medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine 2019; 62: 152930.
14 Wang X, Wang N, Cheung F, Lao L, Li C, Feng Y. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms. J Integr Med 2015; 13: 142-64.
15 Zhai XF, Liu XL, Shen F, Fan J, Ling CQ. Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: a randomized controlled study. Cancer 2018; 124: 2161-8.
16 Zhu H, Hao J, Niu Y, Liu D, Chen D, Wu X. Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. Sci Rep 2018; 8: 7238.
17 Liao YH, Lin CC, Li TC, Lin JG. Utilization pattern of Traditional Chinese Medicine for liver cancer patients in Taiwan. BMC Complement Altern Med 2012; 12: 146.
18 Li FS, Weng JK. Demystifying traditional herbal medicine with modern approach. Nat Plants 2017; 3: 17109.
19 Wu H, Pan L, Gao C, et al. Quercetin inhibits the proliferation of glycolysis-addicted HCC cells by reducing hexokinase 2 and Akt-mTOR pathway. Molecules 2019; 24: 1993.
20 Janiszewska M, Polyak K. A confetti trail of tumour evolution. Nat Cell Biol 2018; 20: 639-41.
21 Wang Z, Han W, Sui X, Fang Y, Pan H. Autophagy: a novel therapeutic target for hepatocarcinoma (Review). Oncol Lett 2014; 7: 1345-51.
22 Liu SH, Chen PS, Huang CC, et al. Unlocking the mystery of the therapeutic effects of Chinese Medicine on cancer. Front Pharmacol 2020; 11: 601785.
23 Lin WF, Lu JY, Cheng BB, Ling CQ. Progress in research on the effects of Traditional Chinese Medicine on the tumor microenvironment. J Integr Med 2017; 15: 282-7.
24 Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
25 Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: 238-55.
26 Zhang RZ, Yu SJ, Bai H, Ning K. TCM-Mesh: the database and analytical system for network pharmacology analysis for TCM preparations. Sci Rep 2017; 7: 2821.
27 Wang C, Vegna S, Jin H, et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 2019; 574: 268-72.
28 Huang JT, Liu SM, Ma H, et al. Systematic review and Meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma. J Cell Physiol 2016; 231: 328-35.
29 Wu X, Ma W, Mei C, et al. Description of CRISPR/Cas 9 development and its prospect in hepatocellular carcinoma treatment. J Exp Clin Cancer Res 2020; 39: 97.
30 Sun YL, Wang WQ, Sun JG, Lu X, YIN CJ. Clinical characteristics of Professor Yin Jian in treating primary liver cancer. Zhong Xi Yi Jie He Gan Bing Za Zhi 2020; 30: 448-9.
31 Qian Y. Clinical experience of Huqi formula in treating primary liver cancer. Zhong Xi Yi Jie He Gan Bing Za Zhi 2019; 29: 106-8.
32 Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer 2018; 7: 235-60.
33 Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer 2020; 9: 682-720.
34 Ling CQ, Fan J, Lin HS, et al. Clinical practice guidelines for the treatment of primary liver cancer with integrative Traditional Chinese And Western Medicine. J Integr Med 2018; 16: 236-48.
35 Fu J, Pang J, Zhao X, Han J. The quantitative ideas and methods in assessment of four properties of Chinese medicinal herbs. Cell Biochem Biophys 2015; 71: 1307-12.
36 Fu X, Mervin LH, Li X, et al. Toward understanding the cold, hot, and neutral nature of Chinese medicines using in silico mode-of-action analysis. J Chem Inf Model 2017; 57: 468-83.
37 Liu YQ, Cheng MC, Wang LX, Zhao N, Xiao HB, Wang ZT. Functional analysis of cultured neural cells for evaluating cold/cool- and hot/warm-natured Chinese herbs. Am J Chin Med 2008; 36: 771-81.
38 Jafari M, Wang Y, Amiryousefi A, Tang J. Unsupervised learning and multipartite network models: a promising approach for understanding traditional medicine. Front Pharmacol 2020; 11: 1319.
39 Zhou Z, Liu X, Wu T, et al. Herbal formula of Bushen Jianpi combined with sorafenib inhibits hepatocellular carcinoma growth by promoting cell apoptosis and blocking the cell cycle. J Tradit Chin Med 2021; 41: 194-202.
40 Yang B, Xiao B, Sun T. Antitumor and immunomodulatory activity of astragalus membranaceus polysaccharides in H22 tumor-bearing mice. Int J Biol Macromol 2013; 62: 287-90.
41 Li W, Hu X, Wang S, et al. Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation. Int J Biol Macromol 2020; 145: 985-97.
42 Kuo CL, Chou HY, Chiu YC, et al. Mitochondrial oxidative stress by Lon-PYCR1 maintains an immunosuppressive tumor microenvironment that promotes cancer progression and metastasis. Cancer Lett 2020; 474: 138-50.
43 Zhang C, Wang N, Tan HY, Guo W, Li S, Feng Y. Targeting VEGF/VEGFRs pathway in the antiangiogenic treatment of human cancers by Traditional Chinese Medicine. Integr Cancer Ther 2018; 17: 582-601.
44 Zhang LJ, Chen L, Lu Y, et al. Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion. Eur J Pharmacol 2010; 643: 195-201.
45 Chiu YJ, Chou SC, Chiu CS, et al. Hepatoprotective effect of the ethanol extract of Polygonum orientale on carbon tetrachloride-induced acute liver injury in mice. J Food Drug Anal 2018; 26: 369-79.
46 Sung YC, Jin PR, Chu LA, et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat Nanotechnol 2019; 14: 1160-9.
47 Luo M, Shang L, Brooks MD, et al. Targeting breast cancer stem cell state equilibrium through modulation of Redox Signaling. Cell Metab 2018; 28: 69-86.
48 Zhang R, Ma C, Wei Y, et al. Isolation, purification, structural characteristics, pharmacological activities, and combined action of Hedyotis diffusa polysaccharides: a review. Int J Biol Macromol 2021; 183: 119-31.
49 Dai ZJ, Wang XJ, Li ZF, et al. Scutellaria barbate extract induces apoptosis of hepatoma H22 cells via the mitochondrial pathway involving caspase-3. World J Gastroenterol 2008; 14: 7321-8.
50 Doan CC, Le TL, Ho NQC, et al. Investigation of bioactive chemical constituents and anti-cancer activity of ethanol extract of Curcuma singularis Gagnep rhizomes. Nat Prod Res 2021: 1-6.
51 Li C, Hong L, Liu C, Min J, Hu M, Guo W. Astragalus polysaccharides increase the sensitivity of SKOV3 cells to cisplatin. Arch Gynecol Obstet 2018; 297: 381-6.
52 Luo Y, Feng Y, Song L, et al. A network pharmacology-based study on the anti-hepatoma effect of Radix Salviae Miltiorrhizae. Chin Med 2019; 14: 27.
53 Su X, Li Y, Jiang M, et al. Systems pharmacology uncover the mechanism of anti-non-small cell lung cancer for Hedyotis diffusa Willd. Biomed Pharmacother 2019; 109: 969-84.
54 Dai ZJ, Wang BF, Lu WF, et al. Total flavonoids of scutellaria barbata inhibit invasion of hepatocarcinoma via MMP/TIMP in vitro. Molecules 2013; 18: 934-50.
55 Doan CC, Le TL, Ho NQC, et al. Bioactive chemical constituents, in vitro anti-proliferative activity and in vivo toxicity of the extract of curcuma singularis gagnep rhizomes. J Ethnopharmacol 2022; 284: 114803.
56 Jeong S, Zheng B, Wang H, Xia Q, Chen L. Nervous system and primary liver cancer. Biochim Biophys Acta Rev Cancer 2018; 1869: 286-92.
57 Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6: 236-47.
58 Yang L, Yu S, Yang Y, et al. Berberine improves liver injury induced glucose and lipid metabolic disorders via alleviating ER stress of hepatocytes and modulating gut microbiota in mice. Bioorg Med Chem 2021; 55: 116598.
59 Jia W, Liang S, Cheng B, Ling C. The role of cancer-associated fibroblasts in hepatocellular carcinoma and the value of Tradi-tional Chinese Medicine treatment. Front Oncol 2021; 11: 763519.
60 Liu R, Zhang H, Zhang Y, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 alpha acts as a tumor suppressor in hepatocellular carcinoma. Tumour Biol 2017; 39: 101042831-7695031.
61 Guo W, Zheng Y, Xu B, et al. Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors. Onco Targets Ther 2017; 10: 1475-85.
62 Yang Z, Sun B, Zhao X, et al. Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vascu- logenic mimicry and poor prognosis. Int J Clin Exp Pathol 2015; 8: 4033-43.
63 Ting CT, Kuo CJ, Hu HY, Lee YL, Tsai TH. Prescription frequency and patterns of Chinese herbal medicine for liver cancer patients in Taiwan: a cross-sectional analysis of the National Health Insurance Research Database. BMC Complement Altern Med 2017; 17: 118.
64 Zheng J, Wu M, Wang H, et al. Network pharmacology to unveil the biological basis of health-strengthening herbal medicine in cancer treatment. Cancers (Basel) 2018; 10 : 461.
Options
Outlines

/

〈 〉